News | August 30, 2023
Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Subscribe To Our Newsletter & Stay Updated
